Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1999 May;23(9):967-9.
doi: 10.1038/sj.bmt.1701765.

Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support

O Sezer  1 , P Schmid, M Shweigert, U Heider, J Eucker, H Harder, P Sinha, H Radtke, K Possinger
Affiliations
Case Reports

Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support

O Sezer et al. Bone Marrow Transplant. 1999 May.

Abstract

In a patient with nephrotic syndrome, renal biopsy revealed AL amyloid deposits. Monoclonal lambda light chains were identified in serum and urine. A low percentage of monoclonal plasma cells was detected in the bone marrow. The patient received four cycles of VAD and subsequent high-dose chemotherapy (HDCT) with melphalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation. Proteinuria rapidly diminished during chemotherapy. Three months after HDCT, the patient has no edema, and no signs of plasma cell dyscrasia are currently detectable. Using VAD before starting HDCT may improve the condition of patients with amyloidosis and reduce transplantation-related morbidity and mortality.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Antibody-mediated resolution of light chain-associated amyloid deposits.
    Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Hrncic R, et al. Am J Pathol. 2000 Oct;157(4):1239-46. doi: 10.1016/S0002-9440(10)64639-1. Am J Pathol. 2000. PMID: 11021828 Free PMC article.
  • Treatment of immunoglobulin light chain amyloidosis.
    Gertz MA, Zeldenrust SR. Gertz MA, et al. Curr Hematol Malig Rep. 2009 Apr;4(2):91-8. doi: 10.1007/s11899-009-0013-6. Curr Hematol Malig Rep. 2009. PMID: 20425420 Review.
  • Primary systemic amyloidosis.
    Gertz MA, Rajkumar SV. Gertz MA, et al. Curr Treat Options Oncol. 2002 Jun;3(3):261-71. doi: 10.1007/s11864-002-0016-1. Curr Treat Options Oncol. 2002. PMID: 12057072 Review.
  • Primary systemic amyloidosis.
    Comenzo RL. Comenzo RL. Curr Treat Options Oncol. 2000 Apr;1(1):83-9. doi: 10.1007/s11864-000-0018-9. Curr Treat Options Oncol. 2000. PMID: 12057064 Review.
  • New advances in renal amyloidosis.
    Nishi S, Alchi B, Imai N, Gejyo F. Nishi S, et al. Clin Exp Nephrol. 2008 Apr;12(2):93-101. doi: 10.1007/s10157-007-0008-3. Epub 2008 Jan 5. Clin Exp Nephrol. 2008. PMID: 18175051 Review.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources